These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35249443)

  • 1. Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation.
    Zhang X; Xin Y; Yang Y; Chen Y; Cao XJ; Wang Y; Fan Q; Zhou X; Li X
    Int J Hyperthermia; 2022; 39(1):437-445. PubMed ID: 35249443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel nomogram for prediction of intrahepatic recurrence-free survival in patients with HCC followed by radiofrequency ablation.
    Wang B; Wu H; Wang S; Zhang ZY; Wu W; Yan K; Yang W
    Br J Radiol; 2024 Mar; 97(1156):844-849. PubMed ID: 38346708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation.
    Guo C; Liang H; Yuan W; Qin Y
    Ann Palliat Med; 2021 Apr; 10(4):4760-4767. PubMed ID: 33966425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival.
    Yang Y; Chen Y; Ye F; Cao X; Xin Y; Wang Y; Lei Y; Li X; Feng D; Zhou X; Fan Q
    Eur Radiol; 2021 May; 31(5):3053-3064. PubMed ID: 33175203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation.
    Chung HA; Kim JH; Hwang Y; Choi HS; Ko SY; Choe WH; Kwon SY
    Saudi J Gastroenterol; 2016; 22(1):57-63. PubMed ID: 26831608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment.
    Liang X; Bu J; Jiang Y; Zhu S; Ye Q; Deng Y; Lu W; Liu Q
    Int J Hyperthermia; 2024; 41(1):2355279. PubMed ID: 38767372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of risk factors and construction of predictive nomogram for early recurrence after radiofrequency ablation of hepatocellular carcinoma].
    Han RC; Ma XH; Wang S; Yang Y; Feng B; Liang M; Zhao XM
    Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):546-552. PubMed ID: 34034474
    [No Abstract]   [Full Text] [Related]  

  • 8. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors.
    Yang Y; Xin Y; Ye F; Liu N; Zhang X; Wang Y; Li X; Fan Q; Zhou X; Chen Y
    Int J Hyperthermia; 2021; 38(1):437-446. PubMed ID: 33724137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study.
    Tan Y; Wang X; Ma K; Zhang L; Li J; Chen P; Zhang B
    Int J Hyperthermia; 2022; 39(1):190-199. PubMed ID: 35042449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study.
    Xin Y; Zhang X; Yang Y; Chen Y; Wang Y; Zhou X; Li X
    J Gastrointest Oncol; 2021 Dec; 12(6):2930-2942. PubMed ID: 35070419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation.
    Sato M; Moriyama M; Fukumoto T; Yamada T; Wake T; Nakagomi R; Nakatsuka T; Minami T; Uchino K; Enooku K; Nakagawa H; Shiina S; Koike K; Fujishiro M; Tateishi R
    Hepatol Int; 2024 Feb; 18(1):131-137. PubMed ID: 37689614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia as a Predictive Factor for Recurrence of Hepatocellular Carcinoma Following Radiofrequency Ablation.
    Jaruvongvanich V; Thamtorawat S; Saiviroonporn P; Pisanuwongse A; Siriwanarangsun P
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1143-1150. PubMed ID: 37116135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
    Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
    J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio to Predict Recurrence in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation.
    Chen Y; Yang Y; Zhang XY; Fan QS; Li X; Xin YJ; Cao XJ; Wang YN; Zhou X
    Cardiovasc Intervent Radiol; 2021 Oct; 44(10):1551-1560. PubMed ID: 34036405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection.
    Shen SL; Fu SJ; Chen B; Kuang M; Li SQ; Hua YP; Liang LJ; Guo P; Hao Y; Peng BG
    Ann Surg Oncol; 2014 Nov; 21(12):3802-9. PubMed ID: 24849520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization.
    Zhu GQ; Wang K; Wang B; Zhou YJ; Yang Y; Chen EB; Zhou ZJ; Zhou SL; Shi YH; Zhou J; Dai Z
    Cancer Manag Res; 2019; 11():63-79. PubMed ID: 30588111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery.
    Okamura Y; Ashida R; Yamamoto Y; Ito T; Sugiura T; Bekku E; Aramaki T; Uesaka K
    Langenbecks Arch Surg; 2016 Mar; 401(2):195-203. PubMed ID: 26943655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    He Q; Xiong Y; Xia P; Yang X; Yu Y; Chen Z
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102283. PubMed ID: 38219821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection.
    Luo H; Li C; Chen L
    Biosci Trends; 2019 May; 13(2):176-181. PubMed ID: 31061272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.